<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Leukocyte-endothelial adhesion in the pathogenesis of inflammation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Leukocyte-endothelial adhesion in the pathogenesis of inflammation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Leukocyte-endothelial adhesion in the pathogenesis of inflammation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amos Etzioni, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Luigi D Notarangelo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inflammation is a crucial process in the normal defense mechanisms against various pathogens, and leukocytes are the principal cellular mediators of inflammation. Inflammation is characterized histologically by the accumulation of leukocytes in the affected tissue due to migration of circulating leukocytes out of the vasculature, a process which is actively mediated and precisely controlled by leukocytes, the cytokines they produce, and the vascular endothelium [<a href="#rid1">1</a>]. However, excessive or uncontrolled inflammatory responses can lead to the pathologic inflammation seen in many rheumatologic and inflammatory disorders.</p><p>Leukocyte trafficking from the bloodstream into tissue is important for surveillance of foreign antigens and for rapid leukocyte accumulation at a site of inflammatory response or tissue injury. Although the importance of leukocyte movement toward sites of inflammation was well-recognized more than a century ago, the precise molecular mechanisms for leukocyte interactions with the endothelium and the emigration of these cells through the endothelium were elucidated only decades later [<a href="#rid2">2</a>].</p><p>The process of leukocyte-endothelial adhesion during inflammation and the various adhesion molecules involved will be discussed in this topic review. Defects and deficiencies in adhesion molecules are presented separately. (See  <a class="medical medical_review" href="/z/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Leukocyte-endothelial adhesion requires dynamic interactions between leukocytes and endothelial cells, involving multiple steps. These steps must be precisely orchestrated to ensure a rapid response with only minimal damage to healthy tissue [<a href="#rid3">3</a>].</p><p>Interactions between leukocytes and the endothelium are mediated by several families of adhesion molecules, each of which participates in a different phase of the process. The surface expression and activation of these molecules during an inflammatory response is tightly controlled under normal conditions [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h1">ADHESION MOLECULES</span><span class="headingEndMark"> — </span>Three families of adhesion molecules are of particular importance to the process of leukocyte-endothelial adhesion  (<a class="graphic graphic_table graphicRef71824" href="/z/d/graphic/71824.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selectins</strong> – Selectins primarily mediate cellular margination and slow rolling. They are located on both leukocytes and endothelial cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Integrins</strong> – Integrins are located on leukocytes and are involved in rolling, but they are most important for arrest on the vascular endothelium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Members of the immunoglobulin superfamily of proteins</strong> – These molecules are important for firm adhesion and transmigration and are largely expressed on endothelial cells.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Selectins</span><span class="headingEndMark"> — </span>Selectins are type I transmembrane glycoproteins expressed on both leukocytes and endothelial cells. The genes for the various members of this family are closely linked on chromosome 1, reflecting their common evolutionary origin. Three selectins exist, including E-, P-, and L-selectin, named for the cell type in which they were originally identified (ie, endothelium, platelet, and leukocyte). All three selectins share similar structural features and an N-terminal lectin-like domain that is crucial for ligand binding. The lectin-like domain is followed by an epidermal growth factor-like domain, a variable number of consensus repeats, a single transmembrane domain, and a short cytoplasmic tail  (<a class="graphic graphic_figure graphicRef69633" href="/z/d/graphic/69633.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>P-selectin</strong> – P-selectin (also called cluster of differentiation molecule 62P or CD62P) is involved in early leukocyte recruitment during the inflammatory response. It is constitutively expressed and stored in secretory granules within endothelial cells. Once the endothelium is stimulated by inflammatory mediators, these granules fuse with the plasma membrane, increasing surface expression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>E-selectin</strong> – E-selectin (CD62E) is synthesized de novo and expressed on endothelial cells and leukocytes after stimulation by various inflammatory mediators, such as interleukin (IL) 1, endotoxin, and tumor necrosis factor (TNF) alpha. Its importance had been illustrated in one patient with a defect in E-selectin production and expression. (See  <a class="medical medical_review" href="/z/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency", section on 'Abnormal E-selectin expression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>L-selectin</strong> – L-selectin (CD62L) is only expressed on leukocytes, unlike the other two selectins. It was originally discovered as a homing molecule that allowed lymphocytes to enter lymphoid tissue. This selectin is unique in that it mediates lymphocyte recruitment on high endothelial venules in lymphatic tissue.</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Selectin ligands</span><span class="headingEndMark"> — </span>The selectins bind to specialized fucosylated sialoglycoconjugates, such as sialyl Lewis X, which decorate selected surface glycoproteins. A well-characterized example is P-selectin glycoprotein ligand 1 (PSGL-1), which is expressed as a dimer on most leukocytes and can interact with all three selectins under inflammatory situations [<a href="#rid5">5,6</a>].</p><p>The importance of fucosylation is demonstrated by the human genetic disease leukocyte-adhesion deficiency (LAD) II, which is due to a mutation in the guanosine diphosphate (GDP) fucose-specific transporter. Defective fucosylation results in an absence of selectin ligands and inability of leukocytes to initiate the adhesion process. Clinically, this disease is characterized by recurrent infections and intellectual disability. (See  <a class="medical medical_review" href="/z/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency", section on 'LAD II'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Integrins</span><span class="headingEndMark"> — </span>Integrins are largely responsible for adhesion of leukocytes to endothelial cells. Integrins are composed of heterodimers of covalently associated alpha and beta protein chains. Individual integrins are categorized and named according to the specific alpha and beta chains present  (<a class="graphic graphic_figure graphicRef54103" href="/z/d/graphic/54103.html" rel="external">figure 2</a>).</p><p>Certain members of the beta-1 and beta-2 subclasses of integrins are primarily responsible for the migration of leukocytes into areas of inflammation.</p><p class="headingAnchor" id="H7"><span class="h3">Beta-1 integrins</span><span class="headingEndMark"> — </span>Eosinophils, lymphocytes, and monocytes express the beta-1 integrin, very late antigen 4 (VLA-4). This molecule binds to endothelial vascular cell adhesion molecule 1 (VCAM-1, an immunoglobulin superfamily protein) and is critical for the accumulation of these cell types at sites of chronic infection [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Beta-2 integrins</span><span class="headingEndMark"> — </span>The beta-2 leukocyte integrins all share a common beta-2 subunit (CD18) and differ in their alpha chains (CD11a, CD11b, and CD11c). The three beta-2 integrins are:</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocyte function-associated antigen 1 (LFA-1, CD11a/CD18b)</p><p class="bulletIndent1"><span class="glyph">●</span>Macrophage antigen 1 (Mac-1, CR3, CD11b/CD18b)</p><p class="bulletIndent1"><span class="glyph">●</span>Glycoprotein 150/95 (gp 150/95, CD11c/CD18b)</p><p></p><p>All three of these integrins are expressed constitutively and must be "activated" in order to become adhesive for their ligands [<a href="#rid8">8</a>]. (See <a class="local">'Leukocyte activation and arrest'</a> below.)</p><p>The importance of the beta-2 integrins is illustrated in a rare condition called LAD I, which is mentioned briefly here and discussed in detail elsewhere. LAD I results from mutations in the gene encoding the beta-2 (CD18) subunit, resulting in deficiencies in the three integrins containing CD18 and impaired migration of leukocytes into sites of inflammation.</p><p>The main clinical features of LAD I are delayed separation of the umbilical cord, recurrent severe infection without pus formation, defective wound healing, and marked leukocytosis (neutrophilia). (See  <a class="medical medical_review" href="/z/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency", section on 'LAD I'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Immunoglobulin superfamily molecules</span><span class="headingEndMark"> — </span>Immunoglobulin superfamily molecules expressed on endothelial cells interact with integrins on leukocytes and are involved in firm adhesion and transendothelial migration. The molecules of this family that are important in leukocyte-endothelial adhesion are intercellular adhesion molecule (ICAM) 1, ICAM-2, and VCAM-1. Variable numbers of these molecules are expressed on the surface of the endothelial cells both constitutively and after cellular activation [<a href="#rid9">9</a>].</p><p>No human disease with congenital defects in the immunoglobulin superfamily molecules has been described. VCAM-1 deletion is lethal in the mouse model [<a href="#rid10">10</a>], and this may also be the case in humans.</p><p>The defining structural characteristic of the immunoglobulin superfamily of molecules is a variable number of intramolecular loops linked by disulfide bonds  (<a class="graphic graphic_figure graphicRef76749" href="/z/d/graphic/76749.html" rel="external">figure 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>ICAM-1 is constitutively expressed at low levels on endothelial cells. Expression is upregulated upon stimulation with multiple factors, including IL-1, TNF-alpha, and endotoxin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ICAM-2 is constitutively expressed at high levels on endothelial cells and does not increase upon cell stimulation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VCAM-1 is only synthesized by and expressed on endothelial cells following stimulation with IL-1, TNF-alpha, or endotoxin. It is not expressed on resting endothelial cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelet-endothelial cell adhesion molecule 1 (PECAM-1 or CD31) is a member of the immunoglobulin superfamily that is expressed at low levels on most leukocytes and platelets but at high levels in endothelial cells where it is localized to intercellular junctions. PECAM-1 is involved in phagocyte transendothelial migration, primarily in migration through the subendothelial basement membrane [<a href="#rid11">11</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h1">THE ADHESION CASCADE</span><span class="headingEndMark"> — </span>Under normal conditions, leukocytes move rapidly in the vasculature, carried along in the laminar flow of blood. The movement of leukocytes from the bloodstream to the tissue occurs in several distinct steps. A simplified version of this process is described in this review  (<a class="graphic graphic_figure graphicRef73528" href="/z/d/graphic/73528.html" rel="external">figure 4</a>). First, under conditions of flow, loose adhesion to the vessel wall causes leukocyte rolling on the endothelium, which primarily occurs in postcapillary venules. This transient and reversible step is a prerequisite for activation of leukocytes. Arrest and firm adhesion occur next, followed by transmigration across the vascular endothelium. Each of these steps involves different adhesion molecules and can be differentially regulated.</p><p class="headingAnchor" id="H11"><span class="h2">Rolling</span><span class="headingEndMark"> — </span>In response to local inflammatory stimuli, endothelial cells become activated and dramatically increase surface expression of selectins. Selectins interact with carbohydrate ligands on the surface of leukocytes. P-selectin glycoprotein ligand 1 (PSGL-1), enriched at the very tip of leukocyte microvilli, plays a major role in this initial interaction [<a href="#rid12">12</a>]. (See <a class="local">'Selectin ligands'</a> above.)</p><p>The interaction of selectins on endothelial cells with their ligands on leukocytes results in slow rolling of leukocytes along vessel walls adjacent to the site of injury. The process of rolling is dependent upon flow. Rolling cells will detach if flow is interrupted because the strength of binding of platelet (P) and leukocyte (L) selectin to their ligands is enhanced by shear stress [<a href="#rid4">4,13</a>]. Neutrophil rolling is primarily mediated by L-selectin on neutrophils and their ligands on endothelial cells [<a href="#rid14">14</a>]. Binding to the selectins tethers the leukocytes, exposing them to chemokines and other stimuli in the microenvironment. No firm adhesion occurs at this very early stage of the cascade.</p><p class="headingAnchor" id="H12"><span class="h2">Leukocyte activation and arrest</span><span class="headingEndMark"> — </span>Slow rolling allows leukocytes to sample the chemokines being synthesized in the local microenvironment. Rolling is reversible until integrins on the leukocytes become sufficiently activated. Chemokines and their receptors provide the activation signals for integrins [<a href="#rid15">15</a>]. Activated integrins on the leukocyte surface then mediate arrest [<a href="#rid16">16</a>].</p><p>All chemokine receptors signal through heterotrimeric G protein-coupled receptors (GPCRs). Binding of a chemokine to its GPCR triggers a complex intracellular signaling network within milliseconds  (<a class="graphic graphic_figure graphicRef63985" href="/z/d/graphic/63985.html" rel="external">figure 5</a>). Repressor activator protein 1 (Rap-1), one of these signaling molecules, has emerged as a key regulator of integrin activation. It transmits regulatory signals to the cell surface that induce conformational changes in integrin molecules [<a href="#rid17">17</a>]. Thus, control of integrin function occurs via signals that originate within the cell cytoplasm in response to changes in the cell's status, a process called "inside-out signaling."</p><p>In response to activation signals, surface integrins undergo a dramatic transition from a bent low-affinity conformation into a fully extended high-affinity structure, with separation of the alpha and beta subunit cytoplasmic tails and opening of the ligand binding site  (<a class="graphic graphic_figure graphicRef63985" href="/z/d/graphic/63985.html" rel="external">figure 5</a>) [<a href="#rid18">18</a>]. This process is called affinity regulation. Kindlin 3 (a signaling protein) and talin 1 (an actin-binding protein) also play a major role in integrin activation and affinity upregulation [<a href="#rid19">19</a>]. Kindlin 3 binds to the intracellular portions of beta-1, 2, and 3 integrins and is believed to enhance their binding to talin 1 at the cell membrane, which leads to increased integrin affinity. Thus, talin 1 and kindlin 3 are critical coactivators and have distinct roles in the induction of integrin conformational rearrangements [<a href="#rid20">20</a>].</p><p>In addition to affinity regulation, the overall strength of adhesiveness (avidity) of the leukocyte-endothelial cell interaction is further increased by the clustering of the integrin molecules on the leukocyte surface [<a href="#rid21">21</a>]. These changes are important for leukocyte arrest.</p><p>Activation of leukocyte integrins results in their increased binding to immunoglobulin superfamily molecules, such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) on endothelial cells. This ensures that adhesion is firm enough to withstand the continuous shear forces present within the blood vessels.</p><p class="headingAnchor" id="H13"><span class="h3">Defects in integrin activation</span><span class="headingEndMark"> — </span>Defective integrin activation underlies the rare disorder, leukocyte-adhesion deficiency (LAD) III. This disease arises from a general defect in the activation of all integrins due to mutations in kindlin 3 [<a href="#rid22">22</a>]. All patients identified had mutations in kindlin 3, although it is possible that, in the future, mutations in other genes involved in integrin activation will be discovered. LAD III is characterized by severe infections, as well as a bleeding tendency due to a defect in beta-3 activation, which is important in platelet aggregation.</p><p>Knockout mice models of various cytoplasmic adaptors for integrin activation, such as diacylglycerol guanine nucleotide exchange factor 1 (CalDAG-GEF1) and kindlin 3, have been very helpful to understanding the role of these molecules. A knockout of talin, which is important in many other cellular functions, was found to be lethal [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/3918.html" rel="external">"Leukocyte-adhesion deficiency", section on 'LAD III'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Crawling and transmigration</span><span class="headingEndMark"> — </span>Transmigration through venular walls is the final step in the process of leukocyte emigration into tissue. Emigration takes place mainly at junctions between endothelial cells (paracellular transmigration) [<a href="#rid24">24</a>], and a leukocyte temporarily arrested at a location distant from a junction site must "crawl" to one nearby while resisting detachment [<a href="#rid25">25</a>]. Specific molecules, such as platelet-endothelial cell adhesion molecule 1 (PECAM-1), are located at these junction sites and actively mediate leukocyte transendothelial migration [<a href="#rid26">26</a>].</p><p>A small fraction of leukocytes follow a different route through the endothelial cell layer, passing directly through endothelial cells via membrane-associated passageways, a process called transcellular emigration [<a href="#rid27">27</a>]. The same families of adhesion molecules may be involved in this form of emigration [<a href="#rid28">28</a>], although the mechanisms have not been extensively studied.</p><p>Leukocytes leaving the vasculature must traverse the endothelial cell layer, the underlying basement membrane, and a loose network of pericytes. Pericytes are long cells composed largely of smooth muscle elements that are wrapped discontinuously around endothelial cells in postcapillary venules. A leukocyte requires approximately 2 to 5 minutes to traverse the endothelial cell layer and 5 to 15 minutes to pass through the basement membrane. Passage through pericytes varies in duration, depending upon the density of these cells in different tissue types [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H15"><span class="h1">CLINICAL APPLICATIONS</span><span class="headingEndMark"> — </span>In many human disorders, excessive inflammation plays a pathogenic role. Several well-established antiinflammatory therapies act, in part, by interfering with the adhesion cascade, including <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, glucocorticoids, <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">colchicine</a>, and others [<a href="#rid29">29-31</a>]. The therapeutic mechanisms of these agents are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7989.html" rel="external">"NSAIDs (including aspirin): Pharmacology and mechanism of action", section on 'Non-prostaglandin-mediated effects'</a> and  <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">"Glucocorticoid effects on the immune system", section on 'Effects on immune cells'</a>.)</p><p>Targeting of adhesion molecules has been proposed as a new direction for the development of antiinflammatory biologic therapies [<a href="#rid32">32</a>]. Several new drugs affecting the adhesion cascade have either become available or are in development. These agents can be divided into four groups [<a href="#rid33">33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-selectins and agents binding selectin ligands (inhibit rolling)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-chemokines and agents inhibiting chemokine receptors (affect the activation phase)</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-integrins and agents inhibiting their receptors (block firm adhesion)</p><p class="bulletIndent1"><span class="glyph">●</span>Inhibitors of intracellular signaling molecules downstream of G protein-coupled receptors (GPCRs)</p><p></p><p>The challenge with these therapies is to identify the key leukocyte subset that initiates a given disease and the trafficking molecules that will most specifically inhibit that subset of cells while leaving most leukocytes unaffected to avoid untoward infectious complications.</p><p>Inflammatory diseases in which trials of these therapies have been performed include asthma [<a href="#rid34">34,35</a>], psoriasis [<a href="#rid36">36-38</a>], inflammatory bowel disease [<a href="#rid39">39-42</a>], multiple sclerosis [<a href="#rid43">43,44</a>], and rheumatoid arthritis [<a href="#rid45">45-47</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Efalizumab</span><span class="headingEndMark"> — </span>Efalizumab is a humanized monoclonal antibody (mAb) against CD11a, the alpha subunit of the beta-2 integrin, lymphocyte function-associated antigen 1 (LFA-1). (See <a class="local">'Beta-2 integrins'</a> above.)</p><p>It was evaluated for use in the treatment of in asthma and psoriasis. However, a small number of cases of progressive multifocal leukoencephalopathy (PML) were reported in patients taking efalizumab continuously for more than three years. PML is a severe demyelinating disease of the central nervous system that is caused by reactivation of the polyomavirus JC (JC virus). This infectious complication led to withdrawal of efalizumab from the American market in 2009 [<a href="#rid48">48</a>]. Other therapies and disorders associated with PML are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">"Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>This devastating complication emphasizes the need for greater understanding of the components of host defense mediated by specific leukocyte subsets and trafficking molecules, as well as a need for more precise and specific inhibitors of leukocyte trafficking.</p><p class="headingAnchor" id="H17"><span class="h2">Natalizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">Natalizumab</a> is a humanized mAb against alpha-4 integrin. Trials of natalizumab have been performed in Crohn disease, multiple sclerosis, and some other diseases.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">Natalizumab</a> can induce remission in Crohn disease, although its use is limited because of its association with serious adverse events, including PML. (See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">Natalizumab</a> is effective for the treatment of relapsing-remitting multiple sclerosis. The formation of inflammatory lesions in patients with multiple sclerosis may involve lymphocytes and monocytes that gain access to the brain parenchyma from the circulation by first adhering to vascular endothelial cells. (See  <a class="medical medical_review" href="/z/d/html/143122.html" rel="external">"Clinical use of monoclonal antibody disease-modifying therapies for multiple sclerosis", section on 'Natalizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">Natalizumab</a> has also been tested in patients with rheumatoid arthritis with positive effect [<a href="#rid45">45-48</a>].</p><p></p><p class="headingAnchor" id="H16232444"><span class="h2">Vedolizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">Vedolizumab</a> is a humanized immunoglobulin G1 (IgG1) mAb against alpha-4-beta-7 integrin that interferes only with the alpha-4-beta-7/mucosal addressin cell adhesion molecule 1 (MAdCAM-1) interaction [<a href="#rid49">49</a>]. It is therefore believed that the effect of vedolizumab will be limited to the gastrointestinal tract, with no effect on the trafficking of lymphocytes to other organs, including the central nervous system [<a href="#rid50">50</a>]. Several clinical trials showed that vedolizumab was effective in the induction and maintenance of remission in active inflammatory bowel disease and had a very good safety profile [<a href="#rid51">51</a>]. Vedolizumab was also found to be effective in the treatment of non-inflammatory bowel disease-related enteropathy [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H1525979009"><span class="h2">Etrolizumab</span><span class="headingEndMark"> — </span>Etrolizumab is a humanized mAb that binds the beta-7 subunit of alpha-4-beta-7 integrin heterodimers, thereby inhibiting interaction with their ligands MAdCAM-1 and E-cadherin, respectively. It has been studied in patients with moderate-to-severe ulcerative colitis [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/4060.html" rel="external">"Management of moderate to severe ulcerative colitis in adults", section on 'Investigational therapies'</a>.)</p><p class="headingAnchor" id="H4154002945"><span class="h2">Ontamalimab</span><span class="headingEndMark"> — </span>Ontamalimab (PF-00547659) is a monoclonal antibody directed against the gut-specific endothelial adhesion molecule MAdCAM-1. While results of earlier phase-II studies in patients with ulcerative colitis and Crohn disease were conflicting [<a href="#rid54">54</a>], a subsequent study enrolling more than 150 Crohn disease patients showed beneficial results for over 72 weeks [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H1575237682"><span class="h2">Abrilumab</span><span class="headingEndMark"> — </span>Abrilumab (AMG181)<strong> </strong>is a subcutaneous antagonist of alpha-4 integrin [<a href="#rid56">56</a>]. Treatment with abrilumab for eight weeks induced remission, mucosal healing, and clinical response in 354 patients with moderate-to-severe ulcerative colitis [<a href="#rid57">57</a>].</p><p>AJM300 is an oral antagonist of alpha-4 integrin [<a href="#rid58">58</a>]. In a multicenter, randomized, placebo-controlled phase-III study involving 203 patients, AJM300 was well-tolerated and induced clinical response [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leukocyte-endothelial adhesion during inflammation is tightly controlled</strong> – Interactions between leukocytes and the endothelium are mediated by several families of adhesion molecules, each of which participates in a different phase of the process. The surface expression and activation of these molecules during an inflammatory response is tightly controlled under normal conditions (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important groups of adhesion molecules</strong> – Important adhesion molecules include selectins, integrins, and members of the immunoglobulin superfamily of proteins. (See <a class="local">'Adhesion molecules'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The adhesion cascade</strong> – The movement of leukocytes from the bloodstream into sites of inflammation may be divided into specific steps: rolling on the endothelium, leukocyte activation and arrest, and transmigration  (<a class="graphic graphic_figure graphicRef73528" href="/z/d/graphic/73528.html" rel="external">figure 4</a>). Each of these steps involves different adhesion molecules. (See <a class="local">'The adhesion cascade'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical applications</strong> – Several well-established antiinflammatory agents act, in part, by inhibiting the expression of adhesion molecules, such as glucocorticoids and nonsteroidal antiinflammatory drugs (NSAIDs). Novel agents are in development, although the beneficial therapeutic effects must be balanced against negative consequences, such as increased susceptibility to infection. (See <a class="local">'Clinical applications'</a> above.)</p><p></p><p class="headingAnchor" id="H1332495664"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zarbock A, Ley K. Mechanisms and consequences of neutrophil interaction with the endothelium. Am J Pathol 2008; 172:1.</a></li><li><a class="nounderline abstract_t">Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7:678.</a></li><li><a class="nounderline abstract_t">Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity 2014; 41:694.</a></li><li><a class="nounderline abstract_t">McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res 2015; 107:331.</a></li><li><a class="nounderline abstract_t">Stadtmann A, Germena G, Block H, et al. The PSGL-1-L-selectin signaling complex regulates neutrophil adhesion under flow. J Exp Med 2013; 210:2171.</a></li><li><a class="nounderline abstract_t">Alon R, Rosen S. Rolling on N-linked glycans: a new way to present L-selectin binding sites. Nat Immunol 2007; 8:339.</a></li><li><a class="nounderline abstract_t">Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011; 118:6743.</a></li><li><a class="nounderline abstract_t">Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol 2013; 55:49.</a></li><li><a class="nounderline abstract_t">Kelly M, Hwang JM, Kubes P. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007; 120:3.</a></li><li><a class="nounderline abstract_t">Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007; 25:619.</a></li><li><a class="nounderline abstract_t">Duncan GS, Andrew DP, Takimoto H, et al. Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions. J Immunol 1999; 162:3022.</a></li><li><a class="nounderline abstract_t">Wagner DD, Frenette PS. The vessel wall and its interactions. Blood 2008; 111:5271.</a></li><li><a class="nounderline abstract_t">Finger EB, Puri KD, Alon R, et al. Adhesion through L-selectin requires a threshold hydrodynamic shear. Nature 1996; 379:266.</a></li><li><a class="nounderline abstract_t">Ivetic A, Hoskins Green HL, Hart SJ. L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling. Front Immunol 2019; 10:1068.</a></li><li><a class="nounderline abstract_t">Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nat Immunol 2008; 9:953.</a></li><li><a class="nounderline abstract_t">Alon R, Ley K. Cells on the run: shear-regulated integrin activation in leukocyte rolling and arrest on endothelial cells. Curr Opin Cell Biol 2008; 20:525.</a></li><li><a class="nounderline abstract_t">Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol 2005; 5:546.</a></li><li><a class="nounderline abstract_t">Wen L, Moser M, Ley K. Molecular mechanisms of leukocyte β2 integrin activation. Blood 2022; 139:3480.</a></li><li><a class="nounderline abstract_t">Wegener KL, Partridge AW, Han J, et al. Structural basis of integrin activation by talin. Cell 2007; 128:171.</a></li><li><a class="nounderline abstract_t">Lefort CT, Ley K. Neutrophil arrest by LFA-1 activation. Front Immunol 2012; 3:157.</a></li><li><a class="nounderline abstract_t">Banno A, Ginsberg MH. Integrin activation. Biochem Soc Trans 2008; 36:229.</a></li><li><a class="nounderline abstract_t">Hidalgo A, Frenette PS. When integrins fail to integrate. Nat Med 2009; 15:249.</a></li><li><a class="nounderline abstract_t">Montanez E, Piwko-Czuchra A, Bauer M, et al. Analysis of integrin functions in peri-implantation embryos, hematopoietic system, and skin. Methods Enzymol 2007; 426:239.</a></li><li><a class="nounderline abstract_t">Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003; 24:327.</a></li><li><a class="nounderline abstract_t">Alon R, Luscinskas FW. Crawling and INTEGRating apical cues. Nat Immunol 2004; 5:351.</a></li><li><a class="nounderline abstract_t">Nourshargh S, Krombach F, Dejana E. The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissues. J Leukoc Biol 2006; 80:714.</a></li><li><a class="nounderline abstract_t">Carman CV, Springer TA. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol 2004; 167:377.</a></li><li><a class="nounderline abstract_t">Engelhardt B, Wolburg H. Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol 2004; 34:2955.</a></li><li><a class="nounderline abstract_t">Ince LM, Weber J, Scheiermann C. Control of Leukocyte Trafficking by Stress-Associated Hormones. Front Immunol 2018; 9:3143.</a></li><li><a class="nounderline abstract_t">Cronstein BN, Molad Y, Reibman J, et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96:994.</a></li><li><a class="nounderline abstract_t">Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep 2008; 10:218.</a></li><li><a class="nounderline abstract_t">Pang X, He X, Qiu Z, et al. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther 2023; 8:1.</a></li><li><a class="nounderline abstract_t">Mackay CR. Moving targets: cell migration inhibitors as new anti-inflammatory therapies. Nat Immunol 2008; 9:988.</a></li><li><a class="nounderline abstract_t">Gauvreau GM, Becker AB, Boulet LP, et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol 2003; 112:331.</a></li><li><a class="nounderline abstract_t">Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 2011; 1:154.</a></li><li><a class="nounderline abstract_t">Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004.</a></li><li><a class="nounderline abstract_t">Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073.</a></li><li><a class="nounderline abstract_t">Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425.</a></li><li><a class="nounderline abstract_t">Sakuraba A, Keyashian K, Correia C, et al. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 2013; 19:621.</a></li><li><a class="nounderline abstract_t">Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132:1672.</a></li><li><a class="nounderline abstract_t">Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005; 6:1182.</a></li><li><a class="nounderline abstract_t">Stefanelli T, Malesci A, De La Rue SA, Danese S. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmun Rev 2008; 7:364.</a></li><li><a class="nounderline abstract_t">Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899.</a></li><li><a class="nounderline abstract_t">Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354:911.</a></li><li><a class="nounderline abstract_t">Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol 2005; 77:129.</a></li><li><a class="nounderline abstract_t">Voulgari PV. Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs 2008; 13:175.</a></li><li><a class="nounderline abstract_t">Genovese MC. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005; 11:S45.</a></li><li class="breakAll">The full FDA statement of withdrawl is available online. http://www.fda.gov/medwatch/safety/2009/safety09.htm#Raptiva (Accessed on January 20, 2011).</li><li><a class="nounderline abstract_t">Luzentales-Simpson M, Pang YCF, Zhang A, et al. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol 2021; 9:612830.</a></li><li><a class="nounderline abstract_t">Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2014; 39:579.</a></li><li><a class="nounderline abstract_t">Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699.</a></li><li><a class="nounderline abstract_t">Akhtar HJ, Nguyen TM, Ma C, Jairath V. Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy. Clin Gastroenterol Hepatol 2022; 20:e614.</a></li><li><a class="nounderline abstract_t">Agrawal M, Verstockt B. Etrolizumab for ulcerative colitis: beyond what meets the eye. Lancet Gastroenterol Hepatol 2022; 7:2.</a></li><li><a class="nounderline abstract_t">Biswas S, Bryant RV, Travis S. Interfering with leukocyte trafficking in Crohn's disease. Best Pract Res Clin Gastroenterol 2019; 38-39:101617.</a></li><li><a class="nounderline abstract_t">D'Haens GR, Reinisch W, Lee SD, et al. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis 2022; 28:1034.</a></li><li><a class="nounderline abstract_t">Mitroulis I, Alexaki VI, Kourtzelis I, et al. Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther 2015; 147:123.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Cyrille M, Hansen MB, et al. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology 2019; 156:946.</a></li><li><a class="nounderline abstract_t">Yoshimura N, Watanabe M, Motoya S, et al. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. Gastroenterology 2015; 149:1775.</a></li><li><a class="nounderline abstract_t">Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol 2022; 7:648.</a></li></ol></div><div id="topicVersionRevision">Topic 3983 Version 24.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18079440" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Mechanisms and consequences of neutrophil interaction with the endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17717539" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Getting to the site of inflammation: the leukocyte adhesion cascade updated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25517612" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Leukocyte migration into inflamed tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25994174" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Selectins: initiators of leucocyte adhesion and signalling at the vascular wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24127491" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The PSGL-1-L-selectin signaling complex regulates neutrophil adhesion under flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17375095" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Rolling on N-linked glycans: a new way to present L-selectin binding sites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021370" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253941" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The molecular basis of leukocyte recruitment and its deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17559914" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Modulating leukocyte recruitment in inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17201681" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Structural basis of integrin regulation and signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10072554" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Genetic evidence for functional redundancy of Platelet/Endothelial cell adhesion molecule-1 (PECAM-1): CD31-deficient mice reveal PECAM-1-dependent and PECAM-1-independent functions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18502843" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The vessel wall and its interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8538793" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Adhesion through L-selectin requires a threshold hydrodynamic shear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31139190" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : L-selectin: A Major Regulator of Leukocyte Adhesion, Migration and Signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711432" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : How chemokines invite leukocytes to dance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18499427" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cells on the run: shear-regulated integrin activation in leukocyte rolling and arrest on endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965491" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intracellular signalling controlling integrin activation in lymphocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35167661" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular mechanisms of leukocyteβ2 integrin activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17218263" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Structural basis of integrin activation by talin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22701459" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Neutrophil arrest by LFA-1 activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18363565" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Integrin activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265824" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : When integrins fail to integrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17697888" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Analysis of integrin functions in peri-implantation embryos, hematopoietic system, and skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12810109" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15052260" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Crawling and INTEGRating apical cues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16857733" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504916" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15376193" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Mini-review: Transendothelial migration of leukocytes: through the front door or around the side of the house?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30687335" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Control of Leukocyte Trafficking by Stress-Associated Hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7543498" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18638431" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Colchicine: its mechanism of action and efficacy in crystal-induced inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36588107" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Targeting integrin pathways: mechanisms and advances in therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711436" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Moving targets: cell migration inhibitors as new anti-inflammatory therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897739" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21547158" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Integrin targeted therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14627785" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679270" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761420" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23429449" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17484865" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369557" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immune cell migration in inflammation: present and future therapeutic targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18486923" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510744" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510745" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548573" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Targeting leukocyte integrins in human diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18321156" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Emerging drugs for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16357750" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Biologic therapies in clinical development for the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16357750" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Biologic therapies in clinical development for the treatment of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33614645" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24479980" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Review article: anti-adhesion therapies for inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964932" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vedolizumab as induction and maintenance therapy for ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33618025" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34798035" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Etrolizumab for ulcerative colitis: beyond what meets the eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31327399" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Interfering with leukocyte trafficking in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34427633" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25448040" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30472236" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26327130" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Safety and Efficacy of AJM300, an Oral Antagonist ofα4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35366419" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : AJM300 (carotegrast methyl), an oral antagonist ofα4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
